SOURCE: DNAPrint Genomics, Inc.

April 27, 2007 07:00 ET

DNAPrint Genomics President & CEO Richard Gabriel Is Interviewed on MN1

SARASOTA, FL -- (MARKET WIRE) -- April 27, 2007 --DNAPrint Genomics, Inc. (OTCBB: DNAG) President and Chief Executive Officer Richard Gabriel was featured in an exclusive Market News First (MN1) interview on Thursday, April 26th, 2007 at 1:30 PM CST.

Chief Executive Officer Richard Gabriel spoke with MN1 host Rich Hancock on www.mn1.com about the Company's innovative and cutting edge technology that aids law enforcement crime scene investigation (CSI) forensics, consumer applications in genealogy ancestry/genetic testing and its pharmaceutical and diagnostic applications.

During the interview Mr. Gabriel highlighted the Company's recent advances in its pharmaceutical and diagnostic, and spoke about its successes in both law enforcement and the growth market of DNAPrint's consumer oriented products.

The interview was podcast and will be archived for six months at the MN1 site, www.mn1.com.

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE. Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:

    Richard Gabriel
    CEO and President
    941 366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848